Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.54 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | NFKBIA | P25963 | 2/20 | 0.46 |
| ▸ | RELA | Q04206 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27988823 | 0.98 | TSHR (0.56) | TSHRCYP3A4MCOLN3GPR35MEN1 | |
| Hydrochloric Acid SCHEMBL9734471 | 0.98 | TSHR (0.56) | TSHRCYP3A4MCOLN3GPR35MEN1 | |
| Nitrobenzene SCHEMBL28208557 | 0.89 | TSHR (0.47) | TSHRCYP3A4MCOLN3MEN1KMT2A | |
| SCHEMBL7592333 | 0.86 | TSHR (0.58) | TSHRCYP3A4MCOLN3GPR35MEN1 | |
| SCHEMBL4067424 | 0.84 | TSHR (0.60) | TSHRCYP3A4MCOLN3GPR35MEN1 | |
| SCHEMBL10619019 | 0.84 | TSHR (0.60) | TSHRCYP3A4MCOLN3GPR35MEN1 | |
| SCHEMBL137704 | 0.82 | TSHR (0.58) | TSHRCYP3A4MCOLN3GPR35MEN1 | |
| SCHEMBL9734767 | 0.82 | TSHR (0.58) | TSHRCYP3A4MCOLN3GPR35MEN1 | |
| SCHEMBL11119285 | 0.82 | TSHR (0.58) | TSHRCYP3A4MCOLN3GPR35MEN1 | |
| SCHEMBL10515856 | 0.82 | TSHR (0.58) | TSHRCYP3A4MCOLN3GPR35MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104556476-B | Method of treating reserve salt of sodium m-nitro-p-toluenesulfonate in electroplating wastewater harmlessly | 东莞市粤威环保科技有限公司 | 2017-02-01 | — | — | CN | claimed |
| CN-108884054-B | Compounds for the treatment of proliferative diseases | 儿童医学中心公司 | 2022-08-02 | — | — | CN | disclosed |
| CN-113860980-A | Method for preparing arylamine compound by photoinduced reduction C-N coupling reaction | 江苏科技大学 | 2021-12-31 | — | — | CN | disclosed |
| CN-108611878-A | A kind of colouring method of SLS/SLA composite materials | 武汉萨普科技股份有限公司 | 2018-10-02 | — | — | CN | disclosed |
| US-20170283787-A1 | METHOD FOR NON-ENZYMATIC COMBINATION OF NUCLEIC ACID CHAINS | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2017-10-05 | — | — | US | disclosed |
| CN-103941538-B | Hardmask surface treatment | 罗门哈斯电子材料有限公司 | 2017-05-24 | — | — | CN | disclosed |
| CN-103492028-B | Sulfonaminoquinoline hepcidin antagonists | 维福（国际）股份公司 | 2017-02-08 | — | — | CN | disclosed |
| EP-2675526-B1 | NOVEL SULFONAMINOQUINOLINE HEPCIDIN ANTAGONISTS | VIFOR (INTERNATIONAL) AG (CH) | 2017-02-01 | — | — | EP | disclosed |
| CN-104556476-B | Method of treating reserve salt of sodium m-nitro-p-toluenesulfonate in electroplating wastewater harmlessly | 东莞市粤威环保科技有限公司 | 2017-02-01 | — | — | CN | disclosed |
| US-9309231-B2 | Bridged ring compounds as hepatitis C virus (HCV) inhibitors and pharmaceutical applications thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-04-12 | — | — | US | disclosed |
| US-5565608-A | Process for the preparation of 2-(substituted)-4-sulfobenzoic acid | ZENECA LIMITED (GB) | 1996-10-15 | — | — | US | disclosed |
| US-5086128-A | HIGH MOLECULAR WEIGHT ARYLENE SULPHIDE POLYMER MELT MIXED WITH AROMATIC NITRO COMPOUND | BAYER AKTIENGESELLSCHAFT (DE) | 1992-02-04 | — | — | US | disclosed |
| EP-0345550-A2 | High molecular weight arylene sulphide polymers | BAYER AG (DE) | 1989-12-13 | — | — | EP | disclosed |
| US-4231958-A | AMINOPHENYLENECARBONYL /AND SULFONYL/IMINONAPHTHALENE INTERMEDIATES | AMERICAN CYANAMID COMPANY (US) | 1980-11-04 | — | — | US | disclosed |
| US-4229370-A | INHIBITORS OF THE COMPLEMENT SYSTEM, IMMUNOLOGY | AMERICAN CYANAMID COMPANY (US) | 1980-10-21 | — | — | US | disclosed |
| US-4229372-A | INHIBITORS OF THE COMPLEMENT SYSTEM, IMMUNOLOGY | AMERICAN CYANAMID COMPANY (US) | 1980-10-21 | — | — | US | disclosed |
| EP-0008154-A1 | Ureylene phenylene anionic naphthalene-sulfonic acids, their use as complement system inhibitors in a body fluid and process for their preparation | AMERICAN CYANAMID COMPANY (US) | 1980-02-20 | — | — | EP | disclosed |
| US-4155930-A | Ureylene phenylene anionic naphthalenesulfonic acids | AMERICAN CYANAMID COMPANY (US) | 1979-05-22 | — | — | US | disclosed |
| US-4155931-A | COMPLEMENT INHIBITORS FOR MAMMALS | AMERICAN CYANAMID COMPANY (US) | 1979-05-22 | — | — | US | disclosed |
| US-4067688-A | Durable press process for cellulosic fiber-containing fabrics utilizing formaldehyde and an aryl sulfonic liquid or acid catalyst | THE STRIKE CORPORATION (US) | 1978-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170283787-A1 | METHOD FOR NON-ENZYMATIC COMBINATION OF NUCLEIC ACID CHAINS | RNGTT, POLRMT, DNTT | TSHR 2392/4885CYP3A4 1474/4885MCOLN3 3728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.